Seaport Therapeutics Announces Science Translational Medicine Peer-Reviewed Publication Featuring GlyphAlloTM (SPT-300) as the First Triglyceride-Mimetic Prodrug to Achieve Therapeutically Relevant Drug Levels in Humans

AI Briefing

• – Seaport Therapeutics announces peer-reviewed publication featuring GlyphAlloTM, a triglyceride-mimetic prodrug that achieves therapeutic drug levels in humans.
• – The publication marks a significant milestone in the development of GlyphAlloTM, a potential treatment for various diseases.
• – GlyphAlloTM was shown to be well-tolerated and effective in achieving therapeutic levels in human clinical trials.